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Rheumatoid arthritis (RA) is an immune-mediated disease of the joints that is characterized
by chronic inﬂammation and synovial hyperplasia that eventually lead to cartilage and bone
destruction. Synovial ﬁbroblasts are mesenchymal cells recognized as a key cell popula-
tion in RA due to their hyperproliferative and hypersensitive properties in the inﬂammatory
milieu and hyperproduction of both inﬂammatory cytokines andmatrix-degrading enzymes.
On the immune cell side, a wealth of evidence has shown that CD4+T-cells, especially IL-17
producing helperT (Th17) cells, play a prominent role, particularly in the initiation of systemic
immune response in RA. However, it is still unclear how the local chronic inﬂammation in
the joint is elicited by a systemic immune response. Recent studies have shed light on the
importance of the interaction between immune and mesenchymal cells in joints includ-
ing synovial ﬁbroblasts. In particular, mesenchymal cells contribute to the Th17-mediated
chronic inﬂammation in RA by promoting themigration ofTh17 cells to the inﬂamed site and
then the homeostatic proliferation and concomitant increase in IL-17 production. In addi-
tion, recent progress in osteoimmunology has provided new insight into the pathogenesis
of the bone destruction which takes place in RA.Th17-related cytokines have been shown
to enhance osteoclastogenesis, mainly via synovial ﬁbroblasts. Thus, mesenchymal cells
are a determinant of the development of RA that links the systemic immune response and
the local disorder in the joints. In addition, the interaction of immune and mesenchymal
cells plays a key role in both the chronic inﬂammation and bone destruction seen in RA.
Elucidation of the precise events involved in this interaction will lead to a better under-
standing of the mechanisms by which chronic inﬂammation and bone destruction in joint
results from a systemic immune response, and also will help provide a molecular basis for
novel therapeutic strategies to treat RA.
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INTRODUCITON
Rheumatoid arthritis (RA) afﬂicts up to 1% of the general popula-
tion worldwide. It is a chronic inﬂammatory disease characterized
by synovial hyperplasia and bone destruction in multiple joints
(Firestein, 2003). Three of the outstanding questions in RA patho-
genesis are how the systemic immune response is elicited by genetic
and/or environmental factors, how this in turn results in local
joint inﬂammation and how inﬂammation causes bone destruc-
tion. In the affected joints, hyperplasia of the synovial membrane
is a hallmark of RA pathology, which is characterized by both
hyperproliferation of synovial ﬁbroblasts and massive inﬁltration
of inﬂammatory immune cells, including CD4+T-cells and innate
immune cells. Synovial ﬁbroblasts have certain unique charac-
teristics, such as hyperproliferative and hyperactive properties in
response to an inﬂammatory environment, and are recognized
as prominent determinants of the joint-speciﬁcity seen in RA.
Therefore, it is important to establish how these pathogenetic
immune cells migrate into joints and contribute to the chronic
inﬂammation andbonedestruction, especially via activationof the
mesenchymal cells resident in joint, such as synovial ﬁbroblasts.
However, so far, despite the clearly evident importance and consid-
erable effort expended, the interplay of immune andmesenchymal
cells in joint is still not fully understood. Though signiﬁcant roles
of B-cells and antibody production are also widely appreciated in
RA, here, we summarize recent ﬁndings on the RA pathogenesis
by focusing on T-cells and synovial ﬁbroblasts.
CD4+T-CELLS ARE INDISPENSABLE FOR THE INITIATION
OF RA
Although the etiology of RA remains unclear, the primary role of
CD4+T-cells in RA has been suggested by various ﬁndings: (1) the
extensive inﬁltration of CD4+T-cell into the inﬂammatory syn-
ovium, (2) the presence of autoantibodies, (3) the association of
RA susceptibility with HLA-DRB1 alleles (Perricone et al., 2011)
and genes related to T-cell function such as PTPN22 (Begovich
et al., 2004; Lee et al., 2005) and CCR6 (Kochi et al., 2010; Stahl
et al., 2010), and (4) the efﬁcacy of a T-cell directed therapeutic
drug, CTLA-4 Ig (Linsley and Nadler, 2009). Importantly, stud-
ies in a variety of animal models have further supported the
importance of CD4+T-cells in RA development.
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Collagen-induced arthritis (CIA) and K/BxN mouse (Kouskoff
et al., 1996)model that recapitulate thewhole process of RA are the
most widely used mouse models. In these models, arthritogenic
antibodies contribute to the development of RA, since transfer
of arthritogenic antibodies can induce arthritis. CD4+T-cells are
required for the full induction of CIA (Ranges et al., 1985) and
K/BxN models (Kouskoff et al., 1996), as the administration of
anti-CD4 depleting antibodies suppresses both the production of
autoantibodies and disease severity (Table 1). In contrast, CAIA
(Kagari et al., 2002) andK/BxNserumtransfer arthritis (Korganow
et al., 1999) do not require T-cells or B-cells, since this form of
arthritis can be induced effectively in T and B-cell-deﬁcient mice.
Thus, it is indicated thatCD4+T-cells are required for the initiation
phase of CIA and K/BxN arthritis partly by producing arthrito-
genic autoantibodies. CD4+T-cells are not strictly necessary after
the production of arthritogenic autoantibodies, although this does
not mean CD4+T-cells have no further role in the disease. Indeed,
they are demonstrably capable of exacerbating arthritis, because
adoptive transfer of a CD4+T-cell subset augments the severity in
the CAIA (Nandakumar et al., 2004) and K/BxN serum transfer
models (Jacobs et al., 2009).
In this review, we divide a whole process of arthritis into
the “initiation,” “inﬂammatory,” and “bone destruction” phases
(Figure 1).We deﬁne the initiation phase as a phase when immune
responses are triggered by an assumed antigen(s) and any appar-
ent symptoms in joints are not yet observed. Inﬂammatory phase
Table 1 |The contribution of proinflammatory cytokines and lymphocytes to the development of mouse models of RA.
IL-17A IL-6 IL-1 TNF CD4+T-cell B-cell
CIA + + ++ + + +
SKG ++ ++ + + + −
F759 ++ ++ NR NR + −
IL-1Ra-deﬁcient ++ − NR ++ + −
CAIA NR − ++ ++ − −
K/BxN serum transfer NR − ++ + − −
TNF-Tg NR − ++ ++ − −
−, Not required; +, partially required; ++, substantially required; NR, not reported.
FIGURE 1 | Possible mechanisms of the initiation, inflammatory, and
bone destruction phases in RA. A variety of different cell populations,
including lymphocytes, innate immune cells, synovial ﬁbroblasts, and
osteoclasts, play a role in the development of RA. Th17 cells contribute
to the development of arthritis in each of the initiation, inﬂammatory, and
bone destructive phases through the production of autoantibodies as
well as the activation of innate immunity and synovial ﬁbroblasts, and
then ultimately, bone destruction. Importantly, synovial ﬁbroblasts
contribute to Th17 immunity in the inﬂammatory phase of arthritis by
promoting the migration of Th17 cells into the inﬂammatory joint, and
then homeostatic proliferation with an increase in IL-17 production. Thus,
the interaction of CD4+T-cells and mesenchymal cells in joints plays a key
role in the pathogenesis of RA in both the inﬂammation and bone
destruction phases.
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starts when any inﬂammatory symptoms such as swelling are rec-
ognized in joints and continues until any structural changes occur.
Bone destruction phase is deﬁned as a phase when structural dam-
ages in bone and cartilage are observed. Although the start point
of initiation phase is difﬁcult to tell in human, this phase must
exist because it takes some time from the start to the point when
clinical symptoms are observed. Thus, it is considered that both
human RA and animal models of RA consist of all these phases.
The signiﬁcance of CD4+T-cells inRAdevelopment is also sup-
ported by T-cell-dependent models such as the SKG mouse, which
has a mutation in ZAP70 (Sakaguchi et al., 2003), the F759 mouse
with a mutation in the gp130 IL-6 receptor subunit (Atsumi et al.,
2002), and the IL-1 receptor antagonist (IL-1Ra)-deﬁcient mouse
(Horai et al., 2000). These mice spontaneously develop arthritis
due to a defect in TCR signaling or the altered sensitivity to inﬂam-
matory cytokines. The adoptive transfer of CD4+T-cells fromSKG
mice into SCID mice induces arthritis, indicating that the arthritis
in SKG mice is CD4+T-cell-dependent (Sakaguchi et al., 2003).
In addition, the arthritis which develops in F759 mice requires
the presence of CD4+T-cells, but not CD8+T-cells or B-cells, in
addition to the gp130 mutation in non-hematopoietic cells (Sawa
et al., 2006). Furthermore, the arthritis in IL-1Ra-deﬁcient mice is
T-cell-dependent, as the T-cells from IL-1Ra-deﬁcientmice induce
disease in nude mice (Horai et al., 2004). Taken together, those T-
cell-dependent mouse models indicate that RA can be provoked
by CD4+T-cells without the need of B-cell help, due to an intrinsic
defect in TCR signaling or altered sensitivity to proinﬂammatory
cytokines (Table 1).
In contrast, arthritis develops in human TNF-α transgenic
(TNF-Tg) mice (Keffer et al., 1991) and mice with the myeloid-
speciﬁc deletion of A20, a negative regulator of NF-κB signaling
(Matmati et al., 2011). These arthritis are thought to recapitulate
the inﬂammatory phase of RA, bypassing the initiation phase of
RA. These mice develop arthritis even on the T, B-cell-deﬁcient
background (Douni et al., 1995). This suggested that hyperac-
tivation of innate immune system is also able to induce RA
(Table 1).
Considering the necessity of CD4+T-cells for the initiation
phase, one of the key questions is whether arthritogenic CD4+T-
cells recognize a speciﬁc antigen, and if so, a joint-speciﬁc antigen
or not. In the form of arthritis in K/BxN and CIA, arthritogenic
CD4+T-cells recognize antigens that are abundant in the joints,
although not exclusively joint-speciﬁc. In contrast, in the arthritis
of F759 mice, the recognition of joint antigens by CD4+T-cells
may not be required, because F759 mice expressing a single TCR
variant that recognizes a non-joint antigen do indeed develop
arthritis (Murakami et al., 2011). Moreover, the antigen speciﬁcity
of arthritogenic CD4+T-cells in SKGmice remains unknown. Fur-
ther studies are thus needed to elucidate the antigen speciﬁcity
of arthritogenic CD4+T-cells, the ﬁnding of which will provide
new insight into how immunological tolerance is broken by the
generation of arthritogenic CD4+T-cells.
Taken together, CD4+T-cells are necessary for at least the initi-
ation phase of arthritis partly by producing arthritogenic anti-
bodies. In contrast, CD4+T-cells may not be required for the
inﬂammatory phase of the disease, especially after arthritogenic
autoantibodies are generated abundantly or innate immunity is
hyper-activated. Nevertheless, CD4+T-cells have been shown to at
least augment the inﬂammatory phase of arthritis development.
Th17 CELLS: AN EMERGING PATHOGENIC SUBSET OF
CD4+T-CELLS
The CD4+ helper T-cells (Th cells), that are differentiated from
naïve CD4+T-cells include Th1, Th2, and Th17 cell subsets. Th17
cells, via their production of IL-17, promote the development of
autoimmune diseases while also protecting host against bacterial
and fungal infection. IL-6 and TGF-β induce Th17 development
and IL-23 promotes Th17 cell expansion (Miossec et al., 2009).
In the past, Th1 cells, which predominantly produce IFN-γ, were
thought to be the principal T-cell player in the pathogenesis of
RA. However, accumulating evidence from animal models in fact
indicates that Th17 immunity is crucially important.
In CIA, accelerated RA development is evident in IFN-γ
receptor-deﬁcient mice (Manoury-Schwartz et al., 1997; Vermeire
et al., 1997). In contrast, disease development is markedly dimin-
ished in mice with IL-17A deﬁciency (Nakae et al., 2003a) or with
antibody-mediated blockade of IL-17 (Lubberts et al., 2004). In the
SKG model, RAG-deﬁcient mice that received naïve SKG CD4+T-
cells exhibited arthritis, along with concomitant Th17 generation.
This arthritis is Th17-dependent, as RAG mice which received a
transfer of IL-17-deﬁcientT-cells did not exhibit any sign of arthri-
tis (Hirota et al., 2007a). Moreover, IL-1Ra-deﬁcient mice with
IL-17A deﬁciency display abrogated arthritis development (Nakae
et al., 2003b). Furthermore, F759 mice with IL-17A deﬁciency
(Ogura et al., 2008) and K/BxN mice treated with a neutraliz-
ing IL-17A antibody exhibited substantially diminished arthritis
(Wu et al., 2010). Taken together, as shown in Table 1, regard-
less of whether the dependency was on IL-6, IL-1, or TNF-α, the
development of arthritiswas shown tobe IL-17-dependent inmost
T-cell-dependent models, suggesting Th17 cell is a pathogenic
subset of CD4+T-cells.
As for the function of IL-17, it augments the production of
proinﬂammatory cytokines, chemokines, and matrix-degrading
enzymes of various kinds of cells such as macrophages, den-
dritic cells (DCs), endothelial cells, and ﬁbroblasts (Miossec et al.,
2009). Thus, Th17 cells exacerbate the inﬂammatory phase of
arthritis through the activation of various kinds of cells in the
inﬂamed joints. In addition, IL-17 is responsible for the produc-
tion of autoantibodies in CIA (Nakae et al., 2003a) and K/BxN
(Wu et al., 2010) mouse models. In particular, IL-17 has been
shown to enhance germinal center (GC) formation in the K/BxN
model. Thus, via IL-17 production, Th17 cells are able to exac-
erbate the initiation phase of arthritis through the production of
autoantibodies. Moreover, IL-17 together with IL-6 ampliﬁes the
production of IL-6 by type 1 collagen+ﬁbroblasts, which in turn
enhances IL-17 production in T-cells (Ogura et al., 2008) as dis-
cussed below. Taken together, Th17 cells can exacerbate arthritis
both in the initiation and inﬂammatory phases.
Cells other than Th17 cells are also reported to produce IL-17 in
arthritis affected joints. In the synoviumof CIA,γδT-cells also pro-
duce IL-17,although few IL-17+γδT-cells are in fact detected in the
affected joints of SKG mice or RA patients (Ito et al., 2009). Mast
cells also produce IL-17 in the inﬂamed joints of RApatients (Hue-
ber et al., 2010a). Although the functional relevance of other IL-17
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producing cells remains to be clariﬁed, considering the wealth of
evidence for the signiﬁcance of CD4+T-cells, it can be concluded
that Th17 cells play a critical role in arthritis development.
Compared with the understanding of the function of Th17
cells, it remains largely unknown how Th17 cell are generated in
the context of arthritis. Recently, several studies on this issue were
reported. In SKG mice, Th17 cells are generated in the presence
of the IL-6 produced by tissue-resident macrophages in response
to C5a, because Th17 cell development is severely impaired in
SKG mice having either a C5aR deﬁciency or a depletion of
macrophages (Hashimoto et al., 2010). In addition, a deﬁciency of
Toll-like receptor (TLR)-4 or administration of aTLR-4 antagonist
suppresses the development of arthritis in IL-1Ra-deﬁcient mice
(Abdollahi-Roodsaz et al., 2008) and CIA (Abdollahi-Roodsaz
et al., 2007) by decreasing the number of Th17 cells. This sug-
gests that TLR-4 signaling is involved in Th17 generation. More-
over, in K/BxN mice, not only arthritis, but also Th17 generation
and the production of arthritogenic autoantibodies cease under
germ-free conditions, whereas the administration of even a single
gut-residing species, segmented ﬁlamentous bacteria, can induce
Th17 generation, GC formation, and the signs of arthritis. Thus,
it is suggested that the gut environment affects the generation of
IL-17+ cells, presumably including Th17 cells, leading to the onset
of arthritis (Wu et al., 2010).
Given the signiﬁcant role of Th17 cells in arthritis in mouse
models, Th17 is now recognized as a promising therapeutic tar-
get. Thus, it is important to clarify the transcriptional mechanisms
regulating Th17 development. ROR nuclear receptors are essential
for Th17 development (Miossec et al., 2009). IkBζ also regulates
Th17 development by cooperating with RORs (Okamoto et al.,
2010). Antagonizing ROR activity has been shown to be effective
in suppressing Th17 differentiation and Th17-mediated autoim-
munity in mice using a synthetic ligand for RORs (Solt et al., 2011)
as well as digoxin and its derivatives (Huh et al., 2011). In addi-
tion, Abs against IL-17A, LY2439821 (Genovese et al., 2010), and
AIN457 (Hueber et al., 2010b) have been shown to be beneﬁcial
for the treatment of RA in human, although they are unexpectedly
less effective than anti-TNF Abs or anti-IL-6 Abs. This suggests
that other IL-17 family members such as IL-17B or IL-17C may
also contribute to RA pathogenesis (Yamaguchi et al., 2007). Alter-
natively, there may be a difference in the extent to which Th17
cells contribute to the pathogenesis of arthritis between mice and
humans. Indeed, T-cells in the synovial ﬂuid of patients with juve-
nile idiopathic arthritis (JIA) easily switch from a Th17 to Th1
phenotype via the intermediate step of a Th1/Th17 mixed phe-
notype (Cosmi et al., 2011), suggesting that human Th17 cells
are more plastic than their mouse counterparts. In line with this,
Ustekinumab, which is a human mAb against IL-12/23p40, sig-
niﬁcantly suppresses psoriatic arthritis in human (Gottlieb et al.,
2009). In addition, a JAK inhibitor tofacitinib (CP690,550) which
inhibits the established CIA presumably by suppressing patho-
genic Th1 and Th17 cells (Ghoreschi et al., 2011), shows clinical
beneﬁt for RA (Kremer et al., 2009; Fleischmann et al., 2012). From
this point of view, either an EP4 antagonist that blocks PGE2–
EP4 signaling (Yao et al., 2009) or a depletion of anti-LT-α Abs
(Chiang et al., 2009), which have been shown to suppress Th17-
mediated autoimmune disease through the inhibition of both Th1
and Th17 immunity in mice, might be therapeutically beneﬁcial
in RA treatment.
Taken together, Th17 cells are crucial immune cells that are
required for the initiation of arthritis and contribute to the aug-
mentation of chronic inﬂammation in joints through the acti-
vation of both innate immunity and mesenchymal cells such as
synovial ﬁbroblasts in joints.
INNATE IMMUNE CELLS: AN ACCELERATOR OF ARTHRITIS
In addition to T-cell inﬁltration, RA exhibits a massive inﬁltration
into affected joints innate immune cells, including macrophages,
neutrophils, mast cells, and DCs. These cells react to comple-
ment or the Fc portion of IgG isotypes via receptors expressed
on their surface. They also produce proinﬂammatory cytokines,
chemokines, and matrix-degrading enzymes that drive chronic
inﬂammation.
The importance of innate immunity in arthritis development
has been shown in both T-cell-dependent and independent mouse
models. In the T-cell-dependent models, SKG mice fail to develop
arthritis when they are raised under a speciﬁc pathogen free (SPF)
condition, whereas SKG mice raised under a conventional envi-
ronment do develop arthritis. In addition, SKG mice under an SPF
condition develop severe arthritis when administrated zymosan, a
crude yeast cell wall extract. Proinﬂammatory cytokines, presum-
ably including TNF-α, which are produced by Dectin-1 expressing
DCs or macrophages in response to zymosan, are involved in this
process (Yoshitomi et al., 2005). In addition,macrophages produce
IL-6 in response to C5a, leading to the generation of Th17 cells in
SKG mice (Hashimoto et al., 2010). These ﬁndings indicate that
activation of adaptive immunity requires innate immunity in the
initiation phase of arthritis.
Among the T-cell-independent models, the K/BxN serum
transfer model has helped address the mechanisms by which acti-
vation of innate immune system triggered by autoantibodies leads
to the development of arthritis. In the K/BxN model, the autoanti-
gen is the glucose-6-phosphate isomerase (GPI) that is expressed
in the joint, although it is not joint-speciﬁc.GPI-anti-GPI immune
complexes bind to articular surfaces, leading to the local augmen-
tation of immune effecter responses in the joint (Matsumoto et al.,
2002). K/BxN serum transfer arthritis requires complement C5
and FcγRIII (Ji et al., 2002). Neutrophils and mast cells are also
required, as mice depleted of neutrophils (Wipke and Allen, 2001)
and mice lacking mast cells (Lee et al., 2002) are both resistant to
the arthritis.
As I mentioned above, TNF-Tg mice and mice with selective
deletion of A20 (TNFAIP3) in myeloid cells do not require either
T-cells or B-cells for the development of arthritis (Douni et al.,
1995; Matmati et al., 2011). These studies suggest that hyper-
activation of innate immunity is sufﬁcient to induce arthritis.
In addition, these ﬁndings prompt a consideration of how it is
that a systemic gene mutation results in local joint inﬂammation.
There may be certain joint-speciﬁc factors, possibly expressed by
synovial ﬁbroblasts, which drive the preferential migration of acti-
vated innate immune cells and thus the ampliﬁcation of chronic
inﬂammation in the affected joints.
Taken together, adaptive immunity requires the activity of
innate immunity for the development of full blown arthritis both
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in the initiation and inﬂammatory phases. In addition, the hyper-
activation of the innate immune response by itself is able to
induce arthritis, presumably through an interaction with synovial
ﬁbroblasts, a unique mesenchymal cell population in joints.
SYNOVIAL FIBROBLASTS: MESENCHYMAL CELLS THAT
DETERMINE JOINT-SPECIFICITY
In general, all RA patients and RA model mice exhibit prolifer-
ative and erosive synovitis in regions adjacent to cartilage and
bone, regardless of differences in the initiating mechanisms. Syn-
oviocytes are divided into synovial ﬁbroblasts of mesenchymal
origin and macrophage-like synoviocytes, depending on their sur-
face markers. RA synovial ﬁbroblasts are key cells in the chronic
inﬂammation which occurs in RA.
Synovial ﬁbroblasts express not only receptors for proinﬂam-
matory cytokines, but also TLRs (Bartok and Firestein, 2010).
In synovitis, synovial ﬁbroblasts exhibit high proliferative activity
and produce large amounts of cytokines, chemokines, and matrix-
degrading enzymes in response to proinﬂammatory cytokines and
TLR ligands, which lead to the exacerbation of synovitis and joint
destruction. For instance, Tenascin-C, an extracellular matrix gly-
coprotein speciﬁcally expressed in inﬂamed joints, was shown to
be an endogenous activator of the TLR-4 expressed by synovial
ﬁbroblasts and macrophages, and is also essential for maintaining
synovitis inK/BxN serum transfer arthritis (Midwood et al., 2009).
Interestingly, the microparticles produced by activated platelets
amplify inﬂammatory arthritis in theK/BxN serum transfermodel
via a collagen-receptor expressed on synovial ﬁbroblasts (Boilard
et al., 2010).
The invasive characteristics of synovial ﬁbroblasts fromRA syn-
ovium have been reported in following studies. Cultured synovial
ﬁbroblasts from human RA synovium were shown to invade and
destroy cartilage when co-transplanted with cartilage into SCID
mice (Muller-Ladner et al., 1996). These transplanted RA syn-
ovial ﬁbroblasts speciﬁcally migrate into a distal cartilage even in
the absence of other immune cells (Lefèvre et al., 2009). Thus,
it is suggested that synovial ﬁbroblasts appear to have intrinsi-
cally invasive properties and to be destined to localize speciﬁcally
in the joint. In addition, the invasive characteristics of synovial
ﬁbroblasts have also been reported in synoviocyte clones obtained
from TNF-Tg mice (Aidinis et al., 2003). These results suggest
that the intrinsically invasive properties of synovial ﬁbroblasts
from inﬂamed joints are stably maintained even after several pas-
sages in culture and that epigenetic modiﬁcation may be involved
in this process. Indeed, the DNA of RA synovial ﬁbroblasts is
hypomethylated both in synovial tissues and in vitro (Karouzakis
et al., 2009). In addition, the ratio of histone acetylase/deacetylase
activity is higher in RA synovial tissue than that in normal synovial
tissue (Huber et al., 2007). Furthermore, synovial ﬁbroblasts pref-
erentially express microRNA 146a and 155, among microRNAs
which function as posttranscriptional repressors of gene expres-
sion (Stanczyk et al., 2008). Further studies are needed to clarify
the mechanisms of epigenetic modiﬁcation and their role in the
maintenance of the activated phenotype of synovial ﬁbroblasts in
arthritic joints.
Given that the inﬁltration of CD4+T-cells in inﬂamed joints is
a hallmark of RA pathology, the interaction of synovial ﬁbroblasts
and CD4+T-cells is assumed to play an important role. By in vitro
co-culture experiments, it has been demonstrated that RA syn-
ovial ﬁbroblasts and CD4+T-cells activate each other through the
ICAM-2 and LFA expressed on synovial ﬁbroblasts and CD4+T-
cells, respectively (Singh et al., 2008). In addition, the IL-15
expressed on RA synovial ﬁbroblasts augments the production of
effecter cytokines from CD4+CD25− cells, while also enhancing
the proliferation of CD4+CD25+Treg cells (Benito-Miguel et al.,
2009). Several reports suggest an antigen-presenting role for syn-
ovial ﬁbroblasts. RA synovial ﬁbroblasts in tissue express MHC
class (Burmester et al., 1987) IFN-γ treated synovial ﬁbroblasts
in vitro stimulate T-cell activation in an MHC class II dependent
manner (Tran et al., 2007). However, the capacity for MHC class II
restricted antigen presentation in synovial ﬁbroblasts and its role
in RA development in vivo remain to be demonstrated.
Importantly, several recent reports have shed light on the rel-
evance of the interaction of CD4+T-cells and mesenchymal cells
in the affected joint in the development of arthritis. In the SKG
model, synovial ﬁbroblasts produce CCL20 in response to proin-
ﬂammatory cytokines such asTNF-α, leading to the recruitment of
CCR6+Th17 cells into the affected joint. This recruitment is essen-
tial, as the administration of a neutralizing anti-CCR6 antibody
ameliorates the development of arthritis (Hirota et al., 2007b).
Likewise, in F759 arthritis, type 1 collagen+ﬁbroblasts produce
CCL20 in response to local stimuli such asmicrobleeding andpref-
erentially recruit CD4+T-cells into inﬂamed joints. The relevance
of this recruitment has been demonstrated, because the inhi-
bition of CCL20 diminished arthritis development (Murakami
et al., 2011). In addition,non-hematopoietic cells,presumably syn-
ovial ﬁbroblasts, produce elevated levels of IL-7 and IL-6, which
enhances the homeostatic proliferation of CD4+T-cells and the
production of IL-17 in Th17 cells, respectively (Sawa et al., 2006;
Ogura et al., 2008). Moreover, IL-6 together with IL-17 ampliﬁes
IL-6 production of synovial ﬁbroblasts (Ogura et al., 2008). In line
with this, by in vitro co-culture system, a JAK inhibitor, Tofacitinib
suppress the production of IL-6 byRA synovial ﬁbroblasts through
the inhibition of IL-17 and IFN-γ by RA CD4+T-cells (Maeshima
et al., 2011).
Considering the important role of synovial ﬁbroblasts, they
may be a good therapeutic target for RA treatment. The induc-
tion of the cell senescence gene in synovial tissues successfully
inhibits rat adjuvant-induced arthritis (Taniguchi et al., 1999).
Yet only a few molecules have been identiﬁed as speciﬁc mark-
ers of synovial ﬁbroblasts to date. Cadherin-11, a relatively spe-
ciﬁc marker, is required for the cellular connectivity of syn-
ovial ﬁbroblasts. Cadherin-11-deﬁcient mice exhibit a hypoplas-
tic synovial lining of the synovium membrane and much less
severe arthritis. Importantly, cadherin-11-directed therapeutics
also markedly reduces synovial inﬂammation (Lee et al., 2007).
Mechanistically, cadherin-11 contributes to the production of IL-
6 in synovial ﬁbroblasts (Chang et al., 2011). The identiﬁcation
of additional speciﬁc markers of synovial ﬁbroblasts will ulti-
mately lead to the establishment of “joint-preferential” therapeutic
strategies.
These ﬁndings, taken together, indicate that synovial ﬁbroblasts
function as a unique“disease ampliﬁer” in the inﬂammatory phase
of RA through both the innate and acquired immunity pathways,
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due to their intrinsically invasive, hypersensitive, and hyperprolif-
erative properties. Studies on animal models of RA have revealed
the role of synovial ﬁbroblasts in Th17 immunity, i.e., promot-
ing the migration of Th17 cells to the affected joints and then
homeostatic proliferation with an accompanying increase in IL-17
production, ultimately leading to the augmentation of the chronic
inﬂammation which characterizes RA (Figure 1).
PROINFLAMMATORY CYTOKINES MEDIATE THE INTERPLAY
BETWEEN IMMUNE CELLS AND JOINTS
In RA synovium, elevated levels of the proinﬂammatory cytokines
IL-1, IL-6, and TNF-α are produced by macrophages and synovial
ﬁbroblasts. These proinﬂammatory cytokines both directly and
indirectly exert their effects through the production of additional
proinﬂammatory cytokines and chemokines as well as matrix-
degrading enzymes, resulting in a cytokine“storm”in the inﬂamed
synovium. The relative contribution of IL-1, IL-6, and TNF-α to
the development and progression of arthritis is different in the
various mouse models (Table 1).
In CIA, the blockade of IL-1 prevents arthritis (Joosten et al.,
1996). IL-6 deﬁciency suppresses disease development (Alonzi
et al., 1998). However, administration of a neutralizing anti-IL-
6 mAb suppresses arthritis development when given early, but
the suppressive effect is not observed when given in the later
phases (Fujimoto et al., 2008). Likewise, the blockade of TNF-
α markedly decreases inﬂammation and joint destruction when
given early (Williams et al., 1992; Joosten et al., 1996). Recently,
the growth factor progranulinwas shown to bind to TNF receptors
and block TNF-α/TNFR signaling. Progranulin reverses inﬂam-
matory arthritis in TNF-Tg mice and prevents the development
of both CIA and CAIA (Tang et al., 2011). In addition, inhibition
of migration of pathogenic T-cells into the joints and the preven-
tion of emigration out of draining lymph nodes are observed in
CIA mice in which TNF/TNFR signaling has been blocked (Notley
et al., 2008). In line with this, impaired migration of T-cells into
the joints is also observed in human RA patients treated with an
anti-TNFα mAb (Taylor et al., 2000).
Overall, it is clear that there is a substantial difference in the
relative contribution of these inﬂammatory cytokines to the devel-
opment of arthritis (Table 1). Dependency on IL-1 and TNFα in
both the T-cell-dependent and independent arthritis models sug-
gests that IL-1 and TNFα may be involved in the inﬂammatory
phase of arthritis in mice. As for human RA, anti-TNF therapies
achieved clinical remission while the IL-1 inhibitor IL-1Ra was less
effective than would be expected from mouse studies, suggesting
that IL-1 in RA may not be as important as it is in mouse arthritis
(Buch et al., 2004). In contrast, the different pattern of depen-
dency on IL-6 in the T-cell-dependent and T-cell-independent
arthritis models suggests that IL-6 may be critically involved in T-
cell mediated arthritis and affect pathogenesis of T-cells. Indeed,
the protective effect of IL-6 blockade in CIA correlates with the
inhibition of Th17 differentiation. In this model, IL-6 blockade
was shown to be effective when administered at an early initiation
phase (Fujimoto et al., 2008). However, a signiﬁcant number of
RA patients with the blockade of IL-6 signaling achieved clinical
remission suggesting that IL-6 plays an important role even in the
inﬂammatory phase in human.
Taken together, proinﬂammatory cytokines mediate the inter-
play between immune cells and joints, leading to the initiation and
augmentation of chronic inﬂammation in RA. The substantial dif-
ferences in cytokine-dependency in animal models may reﬂect the
different effect of each cytokine in each phase of arthritis progres-
sion, in association with the triggering arthritogenic stimuli and
type of the cells that constitute the inﬂammatory synovium.
OSTEOCLASTS; A KEY PLAYER IN THE BONE DESTRUCTION
WHICH OCCURS IN RA
In the pathology of RA, chronic inﬂammation leads to bone
destruction. The synovium is a site where the immune system
interferes with normal bone homeostasis. Bone homeostasis is
maintained by a balance between the continuous resorption activ-
ity of osteoclasts and formation by osteoblasts. In RA, the bone
destruction which takes place is mainly due to the excessive bone
resorption activity of osteoclasts.
Osteoimmunology is a cross-disciplinary research ﬁeld that
investigates the interplay of the bone and immune system at the
molecular level (Takayanagi, 2009). The interaction of osteoclasts
and immune cells is a major topic of interest in this ﬁeld. Stud-
ies of the relationship of osteoclasts and macrophages have led to
important mechanistic insights into osteoclast differentiation. In
addition, studies of the interaction of osteoclasts and T-cells have
contributed to an improved understanding of the mechanism of
bone destruction in RA.
Historically, increasednumbers of osteoclast-like giant cells had
been identiﬁed in the synovium of RA joints by the early 1980s
(Bromley and Woolley, 1984). Based on these pathological ﬁnd-
ings, it was therefore suggested that osteoclasts have an important
role in bone resorption in arthritis. Importantly, osteoclast for-
mation from cultured synovial cells was successfully performed
without the need of any other cells, demonstrating that rheuma-
toid synovial cells contain both osteoclast precursor cells and
osteoclastogenesis-supporting cells (Takayanagi et al., 1997).How-
ever, the molecular mechanism still remained unclear until the
identiﬁcation of RANKL as an osteoclast differentiation factor
expressed on synovial cells (Gravallese et al., 2000; Takayanagi
et al., 2000a).
Osteoclasts are formed when bone marrow cells are cultured
in the presence of M-CSF and RANKL in vitro. Osteoclasts also
are differentiated from bone marrow cells when co-cultured with
mesenchymal cells, such as osteoblasts, in the presence of osteo-
clastogenic factors, including 1,25-dihydroxylvitamin D3, which
induce RANKL expression on mesenchymal cells. Recent studies
indicate that osteocytes, which are embedded in bone, express a
higher amount of RANKL than osteoblasts and are thus the major
source of RANKL in bone remodeling in vivo (Nakashima et al.,
2011; Xiong et al., 2011).
RANKL is essential for osteoclast differentiation, as RANKL-
deﬁcient mice exhibit an osteopetrotic phenotype (Theill et al.,
2002). Of note, a critical role for both RANKL and osteoclasts in
arthritic bone destruction was demonstrated in mouse models of
RA (Pettit et al., 2001; Redlich et al., 2002). Bone destruction did
not occur in the absence of osteoclasts in either of these mod-
els, but a level of inﬂammation similar to that in their wild-type
counterparts was observed, indicating that RANKL and osteoclasts
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are indispensable for bone destruction, but not for inﬂamma-
tion. There is a long-standing debate whether cells other than
synovial ﬁbroblasts express RANKL and thus contribute to osteo-
clastogenesis in arthritis. RANKLwas originally identiﬁed as being
expressed on activatedT-cells (Wong et al., 1997).Histologically, in
the RA synovium, RANKL is expressed by both synovial cells and
T-cells (Kong et al., 1999; Gravallese et al., 2000; Takayanagi et al.,
2000a). In addition, RANKL expression on B-cells in the arthritic
joints of RA patients was reported (Yeo et al., 2012). However, it
still remains unclear the extent to which lymphocytes, as a source
of RANKL, contribute to the bone destruction in arthritis. Mice
bearing a cell type-speciﬁc deletion of RANKL will be required to
decide this issue. Given the important role of RANKL in osteo-
clastogenesis, RANKL is a promising pharmacological target for
the prevention of joint destruction. Indeed, an anti-RANKL anti-
body was recently shown to inhibit joint destruction in human RA
patients (Dore et al., 2010).
The discovery of RANKL shed light on the importance of
understanding the molecular mechanisms that underlie osteoclast
differentiation and function, which has led to the identiﬁcation of
NFATc1 as a master transcription regulator of osteoclastogenesis
(Takayanagi et al., 2002) and other related signaling molecules.
Notably, tyrosine kinases Btk and Tec regulate osteoclastogene-
sis and the inhibition of Tec kinase reduce inﬂammation-induced
bone destruction (Shinohara et al., 2008). Further studies regard-
ing precise mechanisms of osteoclast differentiation and function
are required for a precise molecular basis for novel therapeutic
strategies.
SYNOVIAL FIBROBLASTS PROMOTE OSTEOCLASTOGENESIS
VIA INTERACTION WITH IMMUNE CELLS
Activated T-cells express not only RANKL but also effec-
tor cytokines, including cytokines with either stimulatory or
inhibitory effects on osteoclastogenesis, as shown in Table 2
(Takayanagi et al., 2000b; Takayanagi, 2009). Thus, the osteoclas-
togenic capacity of T-cells is determined by both RANKL and
cytokine expression.
IL-17 is known to enhance osteoclastogenesis in vitro by act-
ing on osteoclastogenesis-supporting cells (Kotake et al., 1999). Of
note, Th17 cells, but neither Th1 cell nor Th2 cells, comprise the
osteoclastogenic helper T subset. Th17 cells do not produce either
IFN-γ or IL-4, each of which inhibits osteoclastogenesis, but do
produce IL-17, which stimulates osteoclastogenesis by its effect on
osteoblasts that act as osteoclastogenesis-supportingmesenchymal
cells (Sato et al., 2006).
Therefore, the presumable roles of IL-17 in the bone destruc-
tion which occurs in RA are as follows. First, IL-17 exerts its
osteoclastogenic effect by stimulating RANKL expression by syn-
ovial ﬁbroblasts. Furthermore, IL-17 up-regulates the expression
of proinﬂammatory cytokines such as IL-1, IL-6, and TNF-α,
which promote osteoclastogenesis through their effects on osteo-
clast precursor cells by enhancing RANK mediated signaling, or
indirectly through upregulation of RANKL expression by synovial
ﬁbroblasts. These events synergistically promote osteoclastic bone
resorption in the inﬂamed synovium.
Besides IL-17, IL-21(Kwok et al., 2012), and IL-22 (Kim
et al., 2012), which are also produced by Th17 cells, stimulate
Table 2 |T-cell-related cytokines and osteoclastogenesis.
Th cell
subsets
Associated
cytokines
Main producer cells Effects on
osteoclastogenesis
Th1 cells IFN-γ Th1 cells and NK cells Inhibition
GM-CSF Th1 cells Inhibition
IL-12 Macrophages and DCs Inhibition
Th2 cells IL-4 Th2 cells and Mast cells Inhibition
IL-10 Th2 cells andTreg cells Inhibition
Th17 cells IL-17 Th17 cells, γδT-cells, and
Mast cells
Activation
RANKL Synoviocytes,
Osteoblasts, andTh17
cells
Activation
IL-1 Macrophages,
Synoviocytes, and Mast
cells
Activation
IL-6 Macrophages, DCs, and
Synoviocytes
Activation
IL-21 Th17 cells, NKT cells Activation
IL-22 Th17 cells, NK cells Activation
IL-23 DCs and Macrophages Activation
TNFα Macrophages and DCs Activation
Treg cells IL-10 Th2 cells andTreg cells Inhibition
TGF-β Treg cells and DCs Activation
The associated cytokines include those produced by T-cells as well as those that
are important for T-cell induction.
osteoclastogenesis mainly by upregulating RANKL expression in
synovial ﬁbroblasts. Thus, it is plausible that synovial ﬁbrob-
lasts augment their capacity to induce osteoclastogenesis in the
presence of Th17 cells.
An important role for Th17 in bone destruction is supported
by studies in mouse models. In CIA, the neutralization of IL-17
after the onset of arthritis reduces the severity of joint destruction
(Lubberts et al., 2004). Although both Th17 cells and γδT-cells
produce IL-17 in the affected joints of CIA, Th17 cells, but not
γδT-cells, have been shown by antibody-mediated depletion and
adoptive transfer studies to reside adjacent to osteoclasts and to
play a prominent role in bone destruction in vivo (Pollinger et al.,
2011).
Osteoclast precursor cells express receptors for proinﬂamma-
tory cytokines. Most of the proinﬂammatory cytokines which
augment inﬂammation also promote osteoclastogenesis by aug-
menting RANK–RANKL signaling, with the exception that TNF-
α and TGF-β together induce osteoclastogenesis even in the
absence of RANK (Kim et al., 2005) This suggests that the inhi-
bition of proinﬂammatory cytokines by neutralizing Abs would
play a dual role in the suppression of inﬂammation and bone
destruction in RA. Interestingly, the inhibition of cathepsin K,
which was thought to be expressed exclusively by osteoclasts
and to play an essential role in bone degradation, has been
shown to play dual role in suppression of osteoclastic bone
resorption and TLR-9 mediated-activation of DCs (Asagiri et al.,
2008).
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Taken together, synovial ﬁbroblasts contribute not only
to chronic inﬂammation but also to the bone destruction
which occurs in RA by promoting RANKL-mediated osteo-
clastogenesis through the interaction of immune cells, mainly
Th17 cells.
CONCLUDING REMARKS
Rheumatoid arthritis is an immune-mediated disease, character-
ized by local inﬂammation and bone destruction in joint as a
result of alteration of systemic immune response. Recent studies
have revealed that Th17 cells and synovial ﬁbroblasts are the crit-
ical regulators. As shown in Figure 1, Th17 cells, differentiated in
the presence of innate immunity, help B-cells produce arthrito-
genic autoantibodies in the initiation phase. In inﬂamed joints,
Th17 cells activate innate immune cells and synovial ﬁbroblasts by
upregulating proinﬂammatory cytokines and matrix-degrading
enzymes, thereby leading to an ampliﬁcation of chronic inﬂam-
mation. Moreover, Th17-related cytokines stimulate the differen-
tiation of osteoclasts, mainly via the synovial ﬁbroblasts in the
joints, which eventually leads to bone destruction. Thus, Th17
cells are not only required for the initiation of the systemic
immune response, they contribute to chronic inﬂammation and
bone destruction. Importantly, synovial ﬁbroblasts contribute to
Th17 immunity in both the inﬂammatory and bone destruction
phases of arthritis by promoting the migration of Th17 cells into
the joint, inducing homeostatic proliferation with a concomitant
increase in IL-17 production and promoting osteoclastogenesis
by upregulation of RANKL expression. It is thus suggested that
synovial ﬁbroblasts connect the systemic immune response to local
joint disorders by their intrinsic characteristics, including their
“hyper-reactivity” and “hyper-chemoattractivity” in response to
inﬂammatory stimuli.
Collectively, the interaction of immune cells and non-
hematopoietic mesenchymal cells in the joints plays a key
role in the pathogenesis of RA in both the inﬂammatory and
bone destruction phases. Elucidation of the precise mechanisms
involved in this interaction will lead to a better understanding
of RA and provide a molecular basis for effective therapeutic
strategies against this disease. Furthermore, the ﬁndings obtained
from such investigation of RA will undoubtedly prove applicable
to other diseases evoked through the interaction of immune and
mesenchymal cells.
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